Log In
BCIQ
Print this Print this
 

TP-1101

  Manage Alerts
Collapse Summary General Information
Company Tolero Pharmaceuticals Inc.
DescriptionSmall molecule activator of pyruvate kinase M2 isozyme (PKM2)
Molecular Target Pyruvate kinase M2 isozyme (PKM2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$780.0M

$200.0M

$580.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/21/2016

$780.0M

$200.0M

$580.0M

Get a free BioCentury trial today